Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
This study examines the antiretroviral activity of ZDV/3TC/NVP in vertically-infected infants and children aged 15 days up to 2 years, and ZDV/3TC/NVP/ABC in vertically-infected infants and children aged 30 days up to 2 years. This study will assess HIV-1 and CD4/CD8 T-cell kinetics, activation, and maturation. It will also test the concept that early (younger than 3 months of age) use of potent, combination antiretroviral therapy will allow the long-term control of viral replication with preservation of normal immune function. \[AS PER AMENDMENT 3/11/98: This study will also examine the an...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Children may be eligible for this study if they:
- • Are 15 days to 2 years old.
- • Have consent of parent or legal guardian.
- • Are HIV-positive.
- • Exclusion Criteria
- Children will not be eligible for this study if they:
- • Have certain infections which require treatment during the study.
- • Have received certain medications.
About National Institute Of Allergy And Infectious Diseases (Niaid)
The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Orleans, Louisiana, United States
Baltimore, Maryland, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
Worcester, Massachusetts, United States
Houston, Texas, United States
Philadelphia, Pennsylvania, United States
New York, New York, United States
Gainesville, Florida, United States
Detroit, Michigan, United States
Norfolk, Virginia, United States
Patients applied
Trial Officials
Katherine Luzuriaga
Study Chair
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials